作者: Nora Sundahl , Alison Tree , Chris Parker
DOI: 10.1007/S11912-020-0868-1
关键词:
摘要: This review summarizes the prospective clinical evidence regarding local therapy in metastatic prostate cancer. The phase 3 STAMPEDE trial showed that radiotherapy confers a survival benefit for newly diagnosed patients with low volume hormone-sensitive cancer (HSPC). No was noted those high disease. A subsequent meta-analysis combining data of HORRAD corroborated these findings. 2 randomized STOMP investigated treatment metastases oligometastatic HSPC, and an improvement hormone therapy–free survival. Local should be offered to HSPC. Early suggests disease might beneficial but larger trials are awaited.